TY - JOUR

T1 - Promising treatment biomarkers in asthma

AU - Bonnesen, Barbara

AU - Jensen, Jens-ulrik S.

AU - Mathioudakis, Alexander G.

AU - Corlateanu, Alexandru

AU - Sivapalan, Pradeesh

PY - 2023

Y1 - 2023

N2 - Asthma is a highly heterogenous disease which researchers over time have attempted to classify into different phenotypes and endotypes to improve diagnosis, prognosis and treatment. Earlier classifications based on reaction to environmental allergens, age, sex and lung function have evolved, and today, the use of precision medicine guided by biomarkers offers new perspectives on asthma management. Identifying biomarkers that may reveal the underlying pathophysiology of the disease will help to select the patients who will benefit most from specific treatments. This review explores the classification of asthma phenotypes and focuses on the most recent advances in using biomarkers to guide treatment.

AB - Asthma is a highly heterogenous disease which researchers over time have attempted to classify into different phenotypes and endotypes to improve diagnosis, prognosis and treatment. Earlier classifications based on reaction to environmental allergens, age, sex and lung function have evolved, and today, the use of precision medicine guided by biomarkers offers new perspectives on asthma management. Identifying biomarkers that may reveal the underlying pathophysiology of the disease will help to select the patients who will benefit most from specific treatments. This review explores the classification of asthma phenotypes and focuses on the most recent advances in using biomarkers to guide treatment.

U2 - 10.3389/fdsfr.2023.1291471

DO - 10.3389/fdsfr.2023.1291471

M3 - Journal article

VL - 3

JO - Frontiers in Drug Safety and Regulation

JF - Frontiers in Drug Safety and Regulation

SN - 2674-0869

ER -